Telix said Part 1 of the ProstACT Global Phase 3 study met its primary objectives for TLX591-Tx in mCRPC. The company reported acceptable safety, no new safety signals and progression plans for Part 2.
The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Norovirus has been making its rounds again during the winter season, causing vomiting, diarrhea and stomach cramps that usually clear within one to three days. There is no specific medication, and hydration, bland foods and strict handwashing are the main measures recommended.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Bariatric surgery procedures have fallen 46.4% since 2022 as prescriptions for semaglutide and tirzepatide rose to 24.17% of eligible adults by Q3 2025, though 75.8% of eligible patients still receive no treatment.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07523230 |
Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department |
COMPLETED | NA |
| NCT07378839 |
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting |
RECRUITING | NA |
| NCT07328477 |
Box Breathing for Anxiety, Pain and Nausea in ERCP Patients |
COMPLETED | NA |
| NCT07208305 |
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting |
RECRUITING | PHASE3 |
| NCT07179094 |
The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash |
NOT_YET_RECRUITING | NA |
| NCT07169851 |
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer |
RECRUITING | PHASE2 |
| NCT07140341 |
A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea) |
COMPLETED | PHASE3 |
| NCT07069023 |
Tiredness and Nausea and Vomiting Management in Oncology Patients |
COMPLETED | NA |
| NCT07051616 |
The Effect of Children's Laughter Video on Oncology Patient |
COMPLETED | NA |
| NCT07029477 |
Incentive Spirometry Versus Massage Therapy Among Post Laparoscopic Cholecystectomy Patients |
COMPLETED | NA |
